For a takeover I am tipping $3 to $5 a share (AUD). I only say that because I feel that if big pharma sees IMU’s suite doing what YF says it can do, and it appears the FDA is going to want it as standard treatment, someone will pull the trigger and grab IMU before it really takes off.
However, if IMU goes it alone, by the end of 2024, with much success expected from trial data, especially with CF33, IMU should be IMO, around the $1.50 to $2.00 mark. As their success spreads around the world through news bulletins, along with plans for production and distribution as a fledgling mini pharmaceutical company, by the end of 2025 I see IMU hitting $4 to $6. With revenue now coming in, the SP will climb each year, $10, $15, $20, and me? I’ll be in full blown retirement checking out Japan and Canada to begin with. My wife might even come too.
